A team of interventional cardiologists from Henry Ford Health’s Center for Structural Heart Disease recently became the first in the United States and the Western Hemisphere to repair a heart valve with severe tricuspid regurgitation in a patient using the investigational K-Clip™ Transvascular Tricuspid Repair System.
AstraZeneca lands FDA approval for AKT inhibitor in biomarker-defined breast cancer subset
AstraZeneca has scored an FDA approval for its AKT inhibitor capivasertib, adding a new targeted therapy to its treatment offerings in breast cancer. The drug,
November 18, 2023